6J Biotechnology (Hong Kong) Limited is a biopharmaceutical company committed to the development of innovative drugs for the treatment of metastasic cancer. It developed a new generation of small-molecule compound 6J-2, which is an innovative drug that is expected to fully and effectively inhibit cancer tumour metastasis. Patents in the United States, Europe and China have been approved, and an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) is being processed. The 6J-2 project won the Gold Medal at Inventions Geneva Evaluation Days (IGED) 2021.